abstract: To analyze the distribution of @entity0 @entity1 /calmodulin-dependent protein kinase II ( @entity4 ) in the adult brain, we generated monoclonal antibodies against the bacterially expressed 490- @entity2 (a.a.) form of @entity4 . One of those, named #18 antibody, was used for this study. Western blot analysis of the adult head extracts showed that the antibody specifically detects multiple bands between 55 and 60 kDa corresponding to the molecular weights of the splicing isoforms of @entity4 . Epitope mapping revealed that it was in the region between 199 and 283 a.a. of @entity4 . Preferential @entity4 immunoreactivity in the embryonic nervous system, adult thoracic ganglion and gut, and larval neuro-muscular junction (NMJ) was consistent with previous observations by in situ hybridization and immunostaining with a polyclonal antibody at the NMJ, indicating that the antibody is applicable to immunohistochemistry. Although @entity4 immunoreactive signal was low in the retina, it was found at regular intervals in the outer margin of the compound eye. These signals were most likely to be interommatidial bristle mechanosensory neurons. @entity4 immunoreactivity in the brain was observed in almost all regions and relatively higher staining was found in the neuropilar region than in the cortex. Higher @entity4 immunoreactivity in the @entity3 ( @entity3 ) was found in the entire gamma lobe including the heel, and dorsal tips of the alpha and alpha' lobes, while cores of alpha and beta lobes were stained light. Finding abundant @entity4 accumulation in the gamma lobe suggested that this lobe might especially require high levels of @entity4 expression to function properly among @entity3 lobes.

title: Immunohistochemical study of Ca2+/calmodulin-dependent protein kinase II in the XXXX brain using a specific monoclonal antibody.

answer: @entity0


abstract: BACKGROUND AIMS:    Invasive @entity2 caused by filamentous fungi and @entity3 are significant causes of morbidity and mortality in immunosuppressed hematology @entity0 . We previously published a method to expand @entity1 -specific T cells for clinical cell therapy. In the present study, we investigated expansion of T cells specific for other fungal pathogens and creation of a broadly reactive @entity4 -cell product. METHODS:    Fungal strains selected were those frequently observed in the clinical hematology setting and included @entity1 , Candida, Fusarium, Rhizopus and Lomentospora/Scedosporium. Four T-cell cultures specific to each fungus were established. We selected lysates of @entity6 , Candida krusei and @entity5 to expand @entity4 cells. Allelic restriction of anti-fungal activity was determined through the use of specific major histocompatibility complex class II-blocking antibodies. RESULTS:    Individual T-cell cultures specific to each fungus could be expanded in vitro, generating predominantly CD4(+) T cells of which 8% to 20% were fungus-specific. We successfully expanded @entity4 cells from the peripheral blood (n   =   8) and granulocyte-colony-stimulating factor-primed stem cell products (n   =   3) of normal donors by using a combination of lysates from @entity6 , Candida krusei and Rhizopus oryzae. Anti-fungal activity was mediated through human leukocyte antigen (HLA)-DR alleles and was maintained when antigen-presenting cells from partially HLA-DRB1-matched donors were used to stimulate T cells. CONCLUSIONS:    We demonstrate a method to manufacture @entity4 -cell products with specificity against a range of clinical fungal pathogens by use of the blood and stem cells of healthy donors as the starting material. The safety and efficacy of these products will need to be tested clinically.

title: Stimulation with lysates of XXXX , Candida krusei and @entity5 maximizes cross-reactivity of anti-fungal T cells.

answer: @entity6


abstract: BACKGROUND AIMS:    Invasive @entity2 caused by filamentous fungi and @entity3 are significant causes of morbidity and mortality in immunosuppressed hematology @entity0 . We previously published a method to expand @entity1 -specific T cells for clinical cell therapy. In the present study, we investigated expansion of T cells specific for other fungal pathogens and creation of a broadly reactive @entity4 -cell product. METHODS:    Fungal strains selected were those frequently observed in the clinical hematology setting and included @entity1 , Candida, Fusarium, Rhizopus and Lomentospora/Scedosporium. Four T-cell cultures specific to each fungus were established. We selected lysates of @entity6 , Candida krusei and @entity5 to expand @entity4 cells. Allelic restriction of anti-fungal activity was determined through the use of specific major histocompatibility complex class II-blocking antibodies. RESULTS:    Individual T-cell cultures specific to each fungus could be expanded in vitro, generating predominantly CD4(+) T cells of which 8% to 20% were fungus-specific. We successfully expanded @entity4 cells from the peripheral blood (n   =   8) and granulocyte-colony-stimulating factor-primed stem cell products (n   =   3) of normal donors by using a combination of lysates from @entity6 , Candida krusei and Rhizopus oryzae. Anti-fungal activity was mediated through human leukocyte antigen (HLA)-DR alleles and was maintained when antigen-presenting cells from partially HLA-DRB1-matched donors were used to stimulate T cells. CONCLUSIONS:    We demonstrate a method to manufacture @entity4 -cell products with specificity against a range of clinical fungal pathogens by use of the blood and stem cells of healthy donors as the starting material. The safety and efficacy of these products will need to be tested clinically.

title: Stimulation with lysates of @entity6 , Candida krusei and XXXX maximizes cross-reactivity of anti-fungal T cells.

answer: @entity5


abstract: The treatment of @entity5 has undergone dramatic changes over the last three decades. More sophisticated diagnostic techniques have allowed early elective repair to be carried out. Improvement has resulted in both morbidity and mortality rates. Investigations such as ultrasound, computerized tomographic scanning and arteriography allow easy confirmation of the diagnosis of @entity3 and permit a better assessment of the extent prior to surgical intervention. Improvement in the pre-operative management, particularly in relation to cardiac, renal, and @entity1 , has led to greatly improved results. The most important change in surgical technique has been repair of the @entity2 rather than resection. Combined with better post-operative intensive care units, this development has contributed to the improved morbidity and mortality rates. Although the complication rate of elective repair is low, the major cause of death remains @entity4 . As a result of all these improvements, indication for repair of @entity5 has been extended to @entity0 over the age of 80. Following surgical repair, most @entity0 can be expected to return to normal lifestyles and lifespans.

title: Current trends in the management of XXXX .

answer: @entity5


abstract: BACKGROUND: @entity4 is increasingly considered to be a chronic inflammatory process. We examined whether genetic variants of the @entity5 ( @entity5 ), which are correlated with impaired innate immunity and with progression of @entity6 , are also associated with @entity3 and predict the risk of @entity1 . METHODS AND RESULTS: Two polymorphisms of the @entity5 gene ( @entity8 and @entity9 ) were determined in 655 @entity0 with angiographically documented @entity3 . All @entity0 participated in a prospective @entity2 -lowering trial evaluating the effect on @entity3 and were randomly assigned to either @entity7 or placebo for 2 years. There were no significant differences between genetically defined subgroups with respect to baseline risk factors, treatment, or in-trial changes of lipid, lipoprotein, or angiographic measurements. Genotype was not associated with progression of @entity4 . In the @entity7 group, 299Gly carriers had a lower risk of @entity1 during follow-up than noncarriers (2.0% versus 11.5%, P=0.045). Among noncarriers, @entity7 reduced the risk of @entity1 from 18.1% to 11.5% (P=0.03), whereas among 299Gly carriers this risk was strikingly reduced from 29.6% to 2.0% (P=0.0002, P=0.025 for interaction). CONCLUSIONS: Among symptomatic @entity0 with documented @entity3 , the @entity5 @entity8 polymorphism was associated with the risk of @entity1 . This variant also modified the efficacy of @entity7 in preventing @entity1 , such that carriers of the variant allele had significantly more benefit from @entity7 treatment.

title: Variants of @entity5 modify the efficacy of statin therapy and the risk of XXXX .

answer: @entity1


abstract: BACKGROUND: @entity4 is increasingly considered to be a chronic inflammatory process. We examined whether genetic variants of the @entity5 ( @entity5 ), which are correlated with impaired innate immunity and with progression of @entity6 , are also associated with @entity3 and predict the risk of @entity1 . METHODS AND RESULTS: Two polymorphisms of the @entity5 gene ( @entity8 and @entity9 ) were determined in 655 @entity0 with angiographically documented @entity3 . All @entity0 participated in a prospective @entity2 -lowering trial evaluating the effect on @entity3 and were randomly assigned to either @entity7 or placebo for 2 years. There were no significant differences between genetically defined subgroups with respect to baseline risk factors, treatment, or in-trial changes of lipid, lipoprotein, or angiographic measurements. Genotype was not associated with progression of @entity4 . In the @entity7 group, 299Gly carriers had a lower risk of @entity1 during follow-up than noncarriers (2.0% versus 11.5%, P=0.045). Among noncarriers, @entity7 reduced the risk of @entity1 from 18.1% to 11.5% (P=0.03), whereas among 299Gly carriers this risk was strikingly reduced from 29.6% to 2.0% (P=0.0002, P=0.025 for interaction). CONCLUSIONS: Among symptomatic @entity0 with documented @entity3 , the @entity5 @entity8 polymorphism was associated with the risk of @entity1 . This variant also modified the efficacy of @entity7 in preventing @entity1 , such that carriers of the variant allele had significantly more benefit from @entity7 treatment.

title: Variants of XXXX modify the efficacy of statin therapy and the risk of @entity1 .

answer: @entity5


abstract: BACKGROUND: Three-spot wrasse, @entity3 , is a marine protogynous hermaphrodite fish. Individuals mature either as @entity1 ( @entity1 ) males or females. Appropriate social cues induce the sex change from @entity1 female to terminal phase (TP) male. However, the molecular mechanisms behind such a sex change remain largely unknown. Recently, the forkhead transcription factor 2 (Foxl2) was identified as an essential regulator of vertebrate ovarian development/function/phenotype. Inspired by this information, we characterized the expression patterns of Foxl2 in the protogynous wrasse assuming Foxl2 as the female-specific marker in this species. METHODS: First, we clonedFoxl2 cDNA from ovary by reverse transcription polymerase chain reaction (RT-PCR) followed by rapid amplification of cDNA ends (RACE). Next, we analysed expression pattern of Foxl2 messenger RNA (mRNA) and protein in gonads of different sexual phases by real time quantitative PCR assay and flour fluorescence immunohistochemical method, respectively. Additionally, we studied the changes in Foxl2 expression pattern during @entity2 ( @entity2 )-induced sex change. RESULTS: The @entity0 sequence (306 AA) of wrasse Foxl2, especially the forkhead domain, shows high identity with that of other reported teleost Foxl2s. Quite unexpectedly, no sexual dimorphism was observable between the testes and ovary in the expression pattern of Foxl2. In female phase fish, signals for Foxl2 protein were detectable in the granulosa cells, but not the theca cells. Transcript levels of Foxl2 in the testes of @entity1 and TP males were identical to that in the ovaries of females and, further, Foxl2 protein was found to be localized in the interstitial cells including tubules and Leydig cells. Treatment with @entity2 induced sex change in male gonads and an up-regulation was seen in the expression of Foxl2 in these gonads. CONCLUSIONS: Unlike in other vertebrates, including teleosts, Foxl2 may have a different role in the naturally sex changing fishes.

title: Expression and localization of forkhead transcriptional factor 2 (Foxl2) in the gonads of protogynous wrasse, XXXX .

answer: @entity3


abstract: OBJECTIVE: To identify the cause of operative failure in @entity0 who have undergone parathyroid surgery for @entity1 . DESIGN: Retrospective case review. @entity0 : @entity0 who had undergone a primary procedure for @entity1 between July 2003 and December 2007. Cases with incomplete post-operative serum @entity2 data were excluded. MAIN OUTCOME MEASURE: Operative failure was defined as failure to achieve normalisation of serum adjusted @entity2 levels post-operatively. RESULTS: A total of 220 primary procedures were conducted over 4.5 years. Data were not available for 16 @entity0 . Thirteen procedures (6.4 per cent) were considered failures, and these cases were individually reviewed and classified according to the reason for failure. CONCLUSION: Establishing the cause of failure following surgery for @entity1 can be a complex task. In some instances, diagnostic uncertainty remains despite detailed biochemical and radiological assessment. This paper outlines our approach to maximising the cure rate at primary surgery.

title: Defining failure after parathyroidectomy for XXXX : case series.

answer: @entity1


abstract: BACKGROUND: Uncontrolled @entity4 ( @entity4 ) results in complex changes in the cardiomyocyte electrical and contractile functioning that promote @entity6 and the continuation of @entity4 . Recently there has been a growing interest in understanding the role of @entity5 proteins (HSPs), which are cytoprotective molecular chaperones, in the pathophysiology of @entity4 . Several groups have examined HSP expression in @entity0 with @entity4 but have yielded mixed results. To allow for better consistency and reproducibility between subjects, we utilized @entity1 models to reproduce AFpromoting conditions to better investigate the role of HSPs in the pathophysiology of @entity4 . METHODS: @entity4 promoting conditions were simulated in @entity1 models with fifteen adult mongrel @entity1 (20.6 to 36.0 kg) divided into three groups: (1) Control (n=5), (2) two week ventricular tachypacing (VTP) induced @entity3 ( @entity3 ) (n=5), and (3) one week @entity4 ( @entity4 ) (n=5). Quick frozen right atrial free wall tissue samples were used for protein isolation and were analyzed via Western blotting with data was expressed as a relative ratio and were analyzed using a two-tailed, unpaired ttest and significance was set at p < 0.05. The expression levels of HSP 90, 70, and 25 were studied along with the phosphorylation status of @entity7 at @entity2 -78. RESULTS: We first examined the effects of the @entity4 and @entity3 heart models on the expression of a select group of HSPs via Western Blot. We found that there was no significant difference in levels of expression of HSP 90, 70, or 25 when either @entity4 or @entity3 models were compared to control @entity1 . The phosphorylation status of @entity7 was significantly decreased in the @entity3 @entity1 model when compared to control (p < 0.0111) and it tended towards a decrease in the @entity4 @entity1 model when compared to control (p=0.0923). CONCLUSION: This study showed that even though the expression levels of HSPs may remain constant, there are protein phosphorylation and dephosphorylation events that occur in @entity4 that may have important consequences in its pathophysiology. It is therefore necessary to investigate the full scale of HSP modifications during @entity4 and @entity4 -promoting conditions.

title: Consequences of Atrial or Ventricular Tachypacing on the XXXX Proteins (HSP) level of Expression and Phosphorylation.

answer: @entity5


abstract: OBJECT: Lumbar discectomy is the most common surgical procedure performed in the US for @entity0 experiencing back and @entity2 from @entity6 . However, not all @entity0 will benefit from lumbar discectomy. @entity0 with certain psychological predispositions may be especially vulnerable to poor clinical outcomes. The goal of this study was therefore to determine the role that preoperative @entity3 and somatic @entity1 have on long-term back and @entity2 , disability, and quality of life (QOL) for @entity0 undergoing single-level lumbar discectomy. METHODS: In 67 adults undergoing discectomy for a single-level @entity6 , the authors determined quantitative measurements of @entity4 (visual analog scale [VAS]), quality of life (36-Item Short Form Health Survey [SF-36]), and disease-specific disability ( @entity5 Index) preoperatively and at 6 weeks, 3, 6, and 12 months after surgery. The degree of preoperative @entity3 and @entity8 was assessed using the Zung Self-Rating @entity3 Scale and a modified somatic perception questionnaire (MSPQ). Multivariate regression analyses were performed to assess associations between Zung Scale and MSPQ scores with achievement of a @entity7 ( @entity7 ) in each outcome measure by 12 months postoperatively. RESULTS: All @entity0 completed 12 months of follow-up. Overall, a significant improvement in VAS @entity2 , @entity4 , @entity5 Index, and SF-36 Physical Component Summary scores was observed by 6 weeks after surgery. Improvements in all outcomes were maintained throughout the 12-month follow-up period. Increasing preoperative @entity3 (measured using the Zung Scale) was associated with a decreased likelihood of achieving an @entity7 in disability (p = 0.006) and QOL (p = 0.04) but was not associated with VAS @entity2 (p = 0.96) or back @entity2 (p = 0.85) by 12 months. Increasing preoperative somatic @entity1 (measured using the MSPQ) was associated with decreased likelihood of achieving an @entity7 in disability (p = 0.002) and QOL (p = 0.03) but was not associated with @entity2 (p = 0.64) or back @entity2 (p = 0.77) by 12 months. CONCLUSIONS: The Zung Scale and MSPQ are valuable tools for stratifying risk in @entity0 who may not experience clinically relevant improvement in disability and QOL after discectomy. Efforts to address these confounding and underlying contributors of @entity3 and heightened somatic @entity1 may improve overall outcomes after lumbar discectomy.

title: Correlation of preoperative XXXX and somatic perception scales with postoperative disability and quality of life after lumbar discectomy.

answer: @entity3


abstract: @entity1 cells can migrate and invade tissue by two modes of motility: mesenchymal and amoeboid. X-ray or y-ray irradiation increases the invasiveness of @entity1 cells with mesenchymal motility through the induction of matrix metalloproteinases (MMP), and this increase is suppressed by MMP inhibitors (MMPI). However, the effects of X-ray or y-ray irradiation on the invasiveness of @entity1 cells with @entity4 remain unclear. We investigated the effect of irradiation on @entity4 by using cells of the @entity0 @entity3 , which exhibits both modes of motility. The X-ray-induced invasiveness of MIAPaCa-2 cells was associated with the upregulation of @entity5 at both the RNA and protein levels and was inhibited by @entity7 treatment. Amoeboid-mesenchymal transition was slightly induced after irradiation. The MMPI treatment caused @entity2 without significant increase in invasiveness, while the @entity6 ( @entity6 ) stimulated amoeboid-mesenchymal transition and enhanced invasiveness under both non-irradiated and irradiated conditions. This @entity6 -induced transition was accompanied by the upregulation of @entity5 mRNA and protein. Exposure to both irradiation and @entity6 further enhanced @entity5 expression and had an additive effect on the invasiveness of MIAPaCa-2 cells. Additionally, exposure to MMPI led to significant suppression of both radiation-induced and the basal invasiveness of MIAPaCa-2 cells. This suggests that @entity6 treatment, especially with concomitant X-ray irradiation, can induce invasion of @entity1 cells and should be used only for certain types of @entity1 cells. Simultaneous use of inhibitors, @entity6 and MMPI may be effective in suppressing invasiveness under both X-ray-irradiated and non-irradiated conditions.

title: X-ray irradiation and Rho-kinase inhibitor additively induce invasiveness of the cells of the XXXX , which exhibits @entity4 .

answer: @entity3


abstract: @entity1 cells can migrate and invade tissue by two modes of motility: mesenchymal and amoeboid. X-ray or y-ray irradiation increases the invasiveness of @entity1 cells with mesenchymal motility through the induction of matrix metalloproteinases (MMP), and this increase is suppressed by MMP inhibitors (MMPI). However, the effects of X-ray or y-ray irradiation on the invasiveness of @entity1 cells with @entity4 remain unclear. We investigated the effect of irradiation on @entity4 by using cells of the @entity0 @entity3 , which exhibits both modes of motility. The X-ray-induced invasiveness of MIAPaCa-2 cells was associated with the upregulation of @entity5 at both the RNA and protein levels and was inhibited by @entity7 treatment. Amoeboid-mesenchymal transition was slightly induced after irradiation. The MMPI treatment caused @entity2 without significant increase in invasiveness, while the @entity6 ( @entity6 ) stimulated amoeboid-mesenchymal transition and enhanced invasiveness under both non-irradiated and irradiated conditions. This @entity6 -induced transition was accompanied by the upregulation of @entity5 mRNA and protein. Exposure to both irradiation and @entity6 further enhanced @entity5 expression and had an additive effect on the invasiveness of MIAPaCa-2 cells. Additionally, exposure to MMPI led to significant suppression of both radiation-induced and the basal invasiveness of MIAPaCa-2 cells. This suggests that @entity6 treatment, especially with concomitant X-ray irradiation, can induce invasion of @entity1 cells and should be used only for certain types of @entity1 cells. Simultaneous use of inhibitors, @entity6 and MMPI may be effective in suppressing invasiveness under both X-ray-irradiated and non-irradiated conditions.

title: X-ray irradiation and Rho-kinase inhibitor additively induce invasiveness of the cells of the @entity3 , which exhibits XXXX .

answer: @entity4


abstract: Craniocervical @entity3 is one of the most common causes of @entity1 in young @entity0 and is occasionally associated with neck manipulation. Identification of individuals at risk will guide risk management. Early recognition of dissection in progress will expedite medical intervention. Study aims were to identify risk factors and presenting features of craniocervical @entity3 . Medical records of @entity0 from the Hunter region of New South Wales, Australia aged  <= 55 years with radiographically confirmed or suspected @entity4 , were retrospectively compared with matched controls with @entity1 from some other cause. Records were inspected for details of clinical features, presenting signs and symptoms and preceding events. Records of 47 dissection @entity0 (27 males, mean age 37.6 years) and 43 controls (22 males, mean age 42.6 years) were inspected. Thirty (64%) dissection @entity0 but only three (7%) controls reported an episode of mild mechanical @entity2 , including manual therapy, to the cervical spine within the preceding three weeks. Mild mechanical @entity2 to the head and neck was significantly associated with craniocervical @entity3 (OR 23.53). Cardiovascular risk factors for @entity1 were less evident in the dissection group (<1 factor per case) compared to the controls (>3).

title: Risk factors and clinical features of craniocervical XXXX .

answer: @entity3


abstract: STUDY OBJECTIVE: To assess the efficacy of computed tomography (CT) in evaluating @entity0 with @entity5 . METHODS: We undertook a retrospective review of all blunt @entity3 @entity0 admitted to the Chi-Mei Medical Center from January 2004 to June 2006. Every @entity0 underwent abdominal CT scan in emergency department and the CT scans were obtained with a four-slice helical CT. Diagnosis of a @entity4 in these @entity0 was by surgical observation or by CT findings. Radiographic @entity4 were classified as deep or superficial lesions. @entity2 were defined as the @entity6 or lacerations >50% thickness of the pancreas. Superficial lesions were described as the @entity6 or lacerations <50% thickness of the pancreas; pancreatic @entity1 ; and focal fluid accumulation around the pancreas RESULTS: Nineteen @entity0 with @entity5 , fourteen males and five females, average age 40.6    21.4 years, were included. Most @entity0 (73.7%) with @entity5 had associated organ injuries. CT was performed in all @entity0 and laparotomy in 14 @entity0 . CT was 78.9% sensitive in detecting @entity5 . All deep pancreatic lesions revealed on CT required surgical treatment, and complication was discovered in two @entity0 undergoing delayed surgery. Superficial lesions were managed conservatively. CONCLUSION: Four-slice helical CT can detect most @entity5 and provide practical therapeutic guidance. Delayed operation might result in complications and is associated with prolonged hospital stays.

title: The efficacy of four-slice helical CT in evaluating XXXX : a single institution experience.

answer: @entity5


abstract: PURPOSE: There is no consensus on the best regimen for the primary treatment of low-risk @entity3 ( @entity3 ). @entity0 AND METHODS: Two commonly used single-drug regimens were compared with respect to the proportion of @entity0 meeting the criteria for a complete response (CR) in a randomized phase III trial conducted by the Gynecologic Oncology Group. Eligibility was purposefully broad to maximize the generalizability of the results and included @entity0 with a WHO risk score of 0 to 6 and @entity0 with @entity1 (limited to lung lesions < 2 cm, adnexa, or vagina) or @entity2 . RESULTS: Two hundred forty @entity0 were enrolled, and 216 were deemed eligible. Biweekly intravenous @entity5 1.25 mg/m   was statistically superior to weekly intramuscular (IM) @entity4 30 mg/m   (CR: 70% v 53%; P = .01). Similarly, in @entity0 with low-risk @entity3 as defined before the 2002 WHO risk score revisions (risk score of 0 to 4 and excluding @entity2 ), response was 58% and 73% in the @entity4 and @entity5 arms, respectively (P = .03). Both regimens were less effective if the WHO risk score was 5 or 6 or if the diagnosis was @entity2 (CR: 9% and 42%, respectively). There were two potential recurrences; one at 4 months ( @entity5 ) and one at 22 months ( @entity4 ). Not all @entity0 completed follow-up. Both regimens were well tolerated. CONCLUSION: The biweekly @entity5 regimen has a higher CR rate than the weekly IM @entity4 regimen in low-risk @entity3 , a generally curable disease.

title: Phase III trial of weekly XXXX or pulsed @entity5 for low-risk @entity3 : a gynecologic oncology group study.

answer: @entity4


abstract: PURPOSE: There is no consensus on the best regimen for the primary treatment of low-risk @entity3 ( @entity3 ). @entity0 AND METHODS: Two commonly used single-drug regimens were compared with respect to the proportion of @entity0 meeting the criteria for a complete response (CR) in a randomized phase III trial conducted by the Gynecologic Oncology Group. Eligibility was purposefully broad to maximize the generalizability of the results and included @entity0 with a WHO risk score of 0 to 6 and @entity0 with @entity1 (limited to lung lesions < 2 cm, adnexa, or vagina) or @entity2 . RESULTS: Two hundred forty @entity0 were enrolled, and 216 were deemed eligible. Biweekly intravenous @entity5 1.25 mg/m   was statistically superior to weekly intramuscular (IM) @entity4 30 mg/m   (CR: 70% v 53%; P = .01). Similarly, in @entity0 with low-risk @entity3 as defined before the 2002 WHO risk score revisions (risk score of 0 to 4 and excluding @entity2 ), response was 58% and 73% in the @entity4 and @entity5 arms, respectively (P = .03). Both regimens were less effective if the WHO risk score was 5 or 6 or if the diagnosis was @entity2 (CR: 9% and 42%, respectively). There were two potential recurrences; one at 4 months ( @entity5 ) and one at 22 months ( @entity4 ). Not all @entity0 completed follow-up. Both regimens were well tolerated. CONCLUSION: The biweekly @entity5 regimen has a higher CR rate than the weekly IM @entity4 regimen in low-risk @entity3 , a generally curable disease.

title: Phase III trial of weekly @entity4 or pulsed @entity5 for low-risk XXXX : a gynecologic oncology group study.

answer: @entity3


abstract: PURPOSE: There is no consensus on the best regimen for the primary treatment of low-risk @entity3 ( @entity3 ). @entity0 AND METHODS: Two commonly used single-drug regimens were compared with respect to the proportion of @entity0 meeting the criteria for a complete response (CR) in a randomized phase III trial conducted by the Gynecologic Oncology Group. Eligibility was purposefully broad to maximize the generalizability of the results and included @entity0 with a WHO risk score of 0 to 6 and @entity0 with @entity1 (limited to lung lesions < 2 cm, adnexa, or vagina) or @entity2 . RESULTS: Two hundred forty @entity0 were enrolled, and 216 were deemed eligible. Biweekly intravenous @entity5 1.25 mg/m   was statistically superior to weekly intramuscular (IM) @entity4 30 mg/m   (CR: 70% v 53%; P = .01). Similarly, in @entity0 with low-risk @entity3 as defined before the 2002 WHO risk score revisions (risk score of 0 to 4 and excluding @entity2 ), response was 58% and 73% in the @entity4 and @entity5 arms, respectively (P = .03). Both regimens were less effective if the WHO risk score was 5 or 6 or if the diagnosis was @entity2 (CR: 9% and 42%, respectively). There were two potential recurrences; one at 4 months ( @entity5 ) and one at 22 months ( @entity4 ). Not all @entity0 completed follow-up. Both regimens were well tolerated. CONCLUSION: The biweekly @entity5 regimen has a higher CR rate than the weekly IM @entity4 regimen in low-risk @entity3 , a generally curable disease.

title: Phase III trial of weekly @entity4 or pulsed XXXX for low-risk @entity3 : a gynecologic oncology group study.

answer: @entity5


abstract: Leptin acts in the brain to regulate food intake and energy expenditure. Leptin also increases renal sympathetic nerve activity and arterial pressure. The divergent signaling capacities of the @entity2 (ObRb) mediate the stimulation of various intracellular pathways that are important for leptin control of physiological processes. We evaluated the cardiovascular and sympathetic consequences of disrupting the signal emanating from tyrosine985 of ObRb. For this, we used @entity2 ) (l/l) @entity1 , which carry a loss of function mutation replacing tyrosine985 of ObRb with leucine. Body weight of l/l @entity1 was not significantly different from wild-type controls. In contrast, radiotelemetry measurements revealed that the l/l @entity1 had higher arterial pressure and heart rate as compared with controls. Ganglionic blockade caused a greater arterial pressure fall in the l/l @entity1 relative to controls. In addition, leptin treatment induced a larger increase in arterial pressure and heart rate in the l/l versus wild-type @entity1 . Finally, we compared the response of renal and brown adipose tissue sympathetic nerve activity to intracerebroventricular injection of leptin (2  g) between l/l and control @entity1 . Leptin-induced @entity0 was greater in l/l @entity1 relative to controls. In contrast, the brown adipose tissue sympathetic nerve activity response to leptin was attenuated in the l/l @entity1 relative to controls. These data indicate that selective loss of @entity2 signaling emanating from tyrosine985 enhances the cardiovascular and renal sympathetic effects of leptin. These findings provide important insight into the molecular mechanisms underlying leptin's effects on the sympathetic cardiovascular function and arterial pressure.

title: Cardiovascular and sympathetic effects of disrupting tyrosine 985 of the XXXX .

answer: @entity2


abstract: BACKGROUND: Although @entity4 -based chemotherapy has become a standard treatment for @entity5 ( @entity5 ), its severe @entity2 limit clinical application and a new alternative regimen is required. The aim of this study was to assess efficacy, survival rate and @entity2 of @entity1 + @entity3 regimen (GP) versus @entity1 + @entity6 regimen (GN) in the treatment of advanced @entity5 @entity0 . METHODS: One hundred and three @entity0 with stage III or IV @entity5 were enrolled into this study, and 52 @entity0 and 51 @entity0 were randomly divided into GP group and GN group respectively. @entity1 1000mg/m   on days 1 and 8 and @entity3 80mg/m   on day 1 were administered to @entity0 in GP group, while @entity1 1000mg/m   on days 1 and 8 and @entity6 25mg/m   on days 1 and 8 were given to @entity0 in GN group. Both regimens were repeated every 3 weeks, no more than 6 cycles for each @entity0 . RESULTS: An objective response rate of 34.6% was observed in GP arm versus 27.5% in GN arm and 1-year survival rate was 68.8% in GP arm and 73.1% in GN arm with no significant difference in statistical analysis (P > 0.05). The median survival time was 19.5 months for GN arm and 14.4 months for GP arm. @entity7 were the major dose-limiting @entity2 . The incidence of @entity7 was significantly higher in GP arm than that in GN arm (51.9% vs 2.0%, P=0.0005). CONCLUSIONS: Both GP regimen and GN regimen are effective regimens when used in Chinese advanced @entity5 @entity0 , however @entity7 in GP regimen are significantly lower than that in GP regimen.

title: [A randomized clinical trial of @entity1 plus XXXX compared with @entity1 plus @entity6 in the treatment of @entity5 ].

answer: @entity3


abstract: BACKGROUND: Although @entity4 -based chemotherapy has become a standard treatment for @entity5 ( @entity5 ), its severe @entity2 limit clinical application and a new alternative regimen is required. The aim of this study was to assess efficacy, survival rate and @entity2 of @entity1 + @entity3 regimen (GP) versus @entity1 + @entity6 regimen (GN) in the treatment of advanced @entity5 @entity0 . METHODS: One hundred and three @entity0 with stage III or IV @entity5 were enrolled into this study, and 52 @entity0 and 51 @entity0 were randomly divided into GP group and GN group respectively. @entity1 1000mg/m   on days 1 and 8 and @entity3 80mg/m   on day 1 were administered to @entity0 in GP group, while @entity1 1000mg/m   on days 1 and 8 and @entity6 25mg/m   on days 1 and 8 were given to @entity0 in GN group. Both regimens were repeated every 3 weeks, no more than 6 cycles for each @entity0 . RESULTS: An objective response rate of 34.6% was observed in GP arm versus 27.5% in GN arm and 1-year survival rate was 68.8% in GP arm and 73.1% in GN arm with no significant difference in statistical analysis (P > 0.05). The median survival time was 19.5 months for GN arm and 14.4 months for GP arm. @entity7 were the major dose-limiting @entity2 . The incidence of @entity7 was significantly higher in GP arm than that in GN arm (51.9% vs 2.0%, P=0.0005). CONCLUSIONS: Both GP regimen and GN regimen are effective regimens when used in Chinese advanced @entity5 @entity0 , however @entity7 in GP regimen are significantly lower than that in GP regimen.

title: [A randomized clinical trial of @entity1 plus @entity3 compared with @entity1 plus @entity6 in the treatment of XXXX ].

answer: @entity5


abstract: BACKGROUND: Although @entity4 -based chemotherapy has become a standard treatment for @entity5 ( @entity5 ), its severe @entity2 limit clinical application and a new alternative regimen is required. The aim of this study was to assess efficacy, survival rate and @entity2 of @entity1 + @entity3 regimen (GP) versus @entity1 + @entity6 regimen (GN) in the treatment of advanced @entity5 @entity0 . METHODS: One hundred and three @entity0 with stage III or IV @entity5 were enrolled into this study, and 52 @entity0 and 51 @entity0 were randomly divided into GP group and GN group respectively. @entity1 1000mg/m   on days 1 and 8 and @entity3 80mg/m   on day 1 were administered to @entity0 in GP group, while @entity1 1000mg/m   on days 1 and 8 and @entity6 25mg/m   on days 1 and 8 were given to @entity0 in GN group. Both regimens were repeated every 3 weeks, no more than 6 cycles for each @entity0 . RESULTS: An objective response rate of 34.6% was observed in GP arm versus 27.5% in GN arm and 1-year survival rate was 68.8% in GP arm and 73.1% in GN arm with no significant difference in statistical analysis (P > 0.05). The median survival time was 19.5 months for GN arm and 14.4 months for GP arm. @entity7 were the major dose-limiting @entity2 . The incidence of @entity7 was significantly higher in GP arm than that in GN arm (51.9% vs 2.0%, P=0.0005). CONCLUSIONS: Both GP regimen and GN regimen are effective regimens when used in Chinese advanced @entity5 @entity0 , however @entity7 in GP regimen are significantly lower than that in GP regimen.

title: [A randomized clinical trial of @entity1 plus @entity3 compared with @entity1 plus XXXX in the treatment of @entity5 ].

answer: @entity6


abstract: BACKGROUND: Although @entity4 -based chemotherapy has become a standard treatment for @entity5 ( @entity5 ), its severe @entity2 limit clinical application and a new alternative regimen is required. The aim of this study was to assess efficacy, survival rate and @entity2 of @entity1 + @entity3 regimen (GP) versus @entity1 + @entity6 regimen (GN) in the treatment of advanced @entity5 @entity0 . METHODS: One hundred and three @entity0 with stage III or IV @entity5 were enrolled into this study, and 52 @entity0 and 51 @entity0 were randomly divided into GP group and GN group respectively. @entity1 1000mg/m   on days 1 and 8 and @entity3 80mg/m   on day 1 were administered to @entity0 in GP group, while @entity1 1000mg/m   on days 1 and 8 and @entity6 25mg/m   on days 1 and 8 were given to @entity0 in GN group. Both regimens were repeated every 3 weeks, no more than 6 cycles for each @entity0 . RESULTS: An objective response rate of 34.6% was observed in GP arm versus 27.5% in GN arm and 1-year survival rate was 68.8% in GP arm and 73.1% in GN arm with no significant difference in statistical analysis (P > 0.05). The median survival time was 19.5 months for GN arm and 14.4 months for GP arm. @entity7 were the major dose-limiting @entity2 . The incidence of @entity7 was significantly higher in GP arm than that in GN arm (51.9% vs 2.0%, P=0.0005). CONCLUSIONS: Both GP regimen and GN regimen are effective regimens when used in Chinese advanced @entity5 @entity0 , however @entity7 in GP regimen are significantly lower than that in GP regimen.

title: [A randomized clinical trial of XXXX plus @entity3 compared with @entity1 plus @entity6 in the treatment of @entity5 ].

answer: @entity1


abstract: BACKGROUND: Although @entity4 -based chemotherapy has become a standard treatment for @entity5 ( @entity5 ), its severe @entity2 limit clinical application and a new alternative regimen is required. The aim of this study was to assess efficacy, survival rate and @entity2 of @entity1 + @entity3 regimen (GP) versus @entity1 + @entity6 regimen (GN) in the treatment of advanced @entity5 @entity0 . METHODS: One hundred and three @entity0 with stage III or IV @entity5 were enrolled into this study, and 52 @entity0 and 51 @entity0 were randomly divided into GP group and GN group respectively. @entity1 1000mg/m   on days 1 and 8 and @entity3 80mg/m   on day 1 were administered to @entity0 in GP group, while @entity1 1000mg/m   on days 1 and 8 and @entity6 25mg/m   on days 1 and 8 were given to @entity0 in GN group. Both regimens were repeated every 3 weeks, no more than 6 cycles for each @entity0 . RESULTS: An objective response rate of 34.6% was observed in GP arm versus 27.5% in GN arm and 1-year survival rate was 68.8% in GP arm and 73.1% in GN arm with no significant difference in statistical analysis (P > 0.05). The median survival time was 19.5 months for GN arm and 14.4 months for GP arm. @entity7 were the major dose-limiting @entity2 . The incidence of @entity7 was significantly higher in GP arm than that in GN arm (51.9% vs 2.0%, P=0.0005). CONCLUSIONS: Both GP regimen and GN regimen are effective regimens when used in Chinese advanced @entity5 @entity0 , however @entity7 in GP regimen are significantly lower than that in GP regimen.

title: [A randomized clinical trial of @entity1 plus @entity3 compared with XXXX plus @entity6 in the treatment of @entity5 ].

answer: @entity1


abstract: @entity2 ( @entity2 ), also referred to as @entity6 , has been proposed as a precursor lesion to microsatellite unstable @entity1 . However, the mechanism of stepwise progression from @entity2 to early @entity1 has been unclear. The purpose of this study was to elucidate the histologic characteristics and possible role of @entity4 , @entity9 , @entity3 , @entity5 , and @entity11 in the development and progression of @entity2 . We analyzed 12 cases of @entity2 with @entity0 progression (SSAN), including 7 cases of intraepithelial @entity7 ( @entity7 ) and 5 cases of @entity1 , and compared them with 53 SSAs and 66 @entity6 ( @entity6 ) by immunohistochemistry and gene mutation analysis. Histologically, 75% (9 of 12) of SSANs showed tubular or tubulovillous growth patterns rather than serrated ones in the @entity1 component. All 5 SSANs with @entity1 lost their serrated structure and developed increased extracellular mucin in their @entity1 component, a consistent feature of @entity8 . Nuclear accumulations of @entity9 and @entity4 were observed in 50% (6 of 12) and 41.7% (5 of 12) of SSANs, respectively, and were exclusively present in @entity7 / @entity1 areas. By contrast, neither nuclear @entity9 nor @entity4 expressions were seen in @entity6 or SSAs (P<0.0001). @entity3 mutations ( @entity10 ) were observed in 45.8% (11 of 24) of @entity6 , 60.9% (14 of 23) of SSAs, and 63.6% (7 of 11) of SSANs, and were equally found in both @entity2 and @entity1 / @entity7 areas of the individual SSANs. @entity5 exon 1 mutations were uncommon in all 3 groups (4.2%, 4.4%, and 0%, respectively). No mutations of @entity11 exon 9 or exon 20 were found in any cases that were examined. These findings suggest that @entity3 mutations may be associated with the pathogenesis of @entity2 , but progression to @entity7 or early @entity1 may be associated with other factors, such as alterations of @entity4 and @entity9 . In addition, our histologic observations suggest a possible close association between SSAN and @entity8 .

title: XXXX with early @entity0 progression: a clinicopathologic and molecular study.

answer: @entity2


abstract: @entity2 ( @entity2 ), also referred to as @entity6 , has been proposed as a precursor lesion to microsatellite unstable @entity1 . However, the mechanism of stepwise progression from @entity2 to early @entity1 has been unclear. The purpose of this study was to elucidate the histologic characteristics and possible role of @entity4 , @entity9 , @entity3 , @entity5 , and @entity11 in the development and progression of @entity2 . We analyzed 12 cases of @entity2 with @entity0 progression (SSAN), including 7 cases of intraepithelial @entity7 ( @entity7 ) and 5 cases of @entity1 , and compared them with 53 SSAs and 66 @entity6 ( @entity6 ) by immunohistochemistry and gene mutation analysis. Histologically, 75% (9 of 12) of SSANs showed tubular or tubulovillous growth patterns rather than serrated ones in the @entity1 component. All 5 SSANs with @entity1 lost their serrated structure and developed increased extracellular mucin in their @entity1 component, a consistent feature of @entity8 . Nuclear accumulations of @entity9 and @entity4 were observed in 50% (6 of 12) and 41.7% (5 of 12) of SSANs, respectively, and were exclusively present in @entity7 / @entity1 areas. By contrast, neither nuclear @entity9 nor @entity4 expressions were seen in @entity6 or SSAs (P<0.0001). @entity3 mutations ( @entity10 ) were observed in 45.8% (11 of 24) of @entity6 , 60.9% (14 of 23) of SSAs, and 63.6% (7 of 11) of SSANs, and were equally found in both @entity2 and @entity1 / @entity7 areas of the individual SSANs. @entity5 exon 1 mutations were uncommon in all 3 groups (4.2%, 4.4%, and 0%, respectively). No mutations of @entity11 exon 9 or exon 20 were found in any cases that were examined. These findings suggest that @entity3 mutations may be associated with the pathogenesis of @entity2 , but progression to @entity7 or early @entity1 may be associated with other factors, such as alterations of @entity4 and @entity9 . In addition, our histologic observations suggest a possible close association between SSAN and @entity8 .

title: @entity2 with early XXXX progression: a clinicopathologic and molecular study.

answer: @entity0


abstract: The progression of @entity5 -induced @entity0 @entity3 ( @entity1 ) was characterised using quantitative and semiquantitative immunohistochemistry for @entity4 ( @entity4 ), basement membrane laminin (BML) and trypsinogen (TG). Samples were taken 5-20 months after initiation. High @entity4 -labelling indices ( @entity4 LIs) were measured 5 months after the induction of atypical acinar cell nodules (AACNs), which decreased later and stagnated until a further decline in the month 10 @entity2 . Then a second premalignant proliferative wave was observed (month 13) within the @entity2 stage. Later, in month 20 differentiated ACs @entity4 LIs fell to the host tissue level but were found highest in the month 20 anaplastic ACs indicating a switch to malignant proliferation. Month 20 invasive ACs showed a number of separate proliferative foci. In early AACNs, BML decreased and remained low till the local maximum in the month 13 @entity2 . Invasive ACs did not express BML. Month 5 AACN and differentiated @entity1 were TG deficient but anaplastic @entity1 regained its TG expression. However invasive @entity1 was again TG negative. These results are discussed in combination with our previous data on progressional changes of autophagic capacity and microvessel densities.

title: Characterisation of the progression of @entity5 -induced @entity0 XXXX by proliferative cell nuclear antigen, basement membrane laminin and trypsinogen immunohistochemistry.

answer: @entity3


abstract: The progression of @entity5 -induced @entity0 @entity3 ( @entity1 ) was characterised using quantitative and semiquantitative immunohistochemistry for @entity4 ( @entity4 ), basement membrane laminin (BML) and trypsinogen (TG). Samples were taken 5-20 months after initiation. High @entity4 -labelling indices ( @entity4 LIs) were measured 5 months after the induction of atypical acinar cell nodules (AACNs), which decreased later and stagnated until a further decline in the month 10 @entity2 . Then a second premalignant proliferative wave was observed (month 13) within the @entity2 stage. Later, in month 20 differentiated ACs @entity4 LIs fell to the host tissue level but were found highest in the month 20 anaplastic ACs indicating a switch to malignant proliferation. Month 20 invasive ACs showed a number of separate proliferative foci. In early AACNs, BML decreased and remained low till the local maximum in the month 13 @entity2 . Invasive ACs did not express BML. Month 5 AACN and differentiated @entity1 were TG deficient but anaplastic @entity1 regained its TG expression. However invasive @entity1 was again TG negative. These results are discussed in combination with our previous data on progressional changes of autophagic capacity and microvessel densities.

title: Characterisation of the progression of XXXX -induced @entity0 @entity3 by proliferative cell nuclear antigen, basement membrane laminin and trypsinogen immunohistochemistry.

answer: @entity5


abstract: The progression of @entity5 -induced @entity0 @entity3 ( @entity1 ) was characterised using quantitative and semiquantitative immunohistochemistry for @entity4 ( @entity4 ), basement membrane laminin (BML) and trypsinogen (TG). Samples were taken 5-20 months after initiation. High @entity4 -labelling indices ( @entity4 LIs) were measured 5 months after the induction of atypical acinar cell nodules (AACNs), which decreased later and stagnated until a further decline in the month 10 @entity2 . Then a second premalignant proliferative wave was observed (month 13) within the @entity2 stage. Later, in month 20 differentiated ACs @entity4 LIs fell to the host tissue level but were found highest in the month 20 anaplastic ACs indicating a switch to malignant proliferation. Month 20 invasive ACs showed a number of separate proliferative foci. In early AACNs, BML decreased and remained low till the local maximum in the month 13 @entity2 . Invasive ACs did not express BML. Month 5 AACN and differentiated @entity1 were TG deficient but anaplastic @entity1 regained its TG expression. However invasive @entity1 was again TG negative. These results are discussed in combination with our previous data on progressional changes of autophagic capacity and microvessel densities.

title: Characterisation of the progression of @entity5 -induced XXXX @entity3 by proliferative cell nuclear antigen, basement membrane laminin and trypsinogen immunohistochemistry.

answer: @entity0


abstract: The aim of this study was to evaluate hemostatic variables in @entity0 according to different body mass index (BMI) values, and then correlate them with some metabolic parameters - fasting insulin and @entity3 , total @entity2 , high-density lipoprotein (HDL)- @entity2 , low-density lipoprotein (LDL)- @entity2 and @entity4 . Eighty-four female @entity0 aged 18-39 years were recruited, and agreed to participate in the study. The study group was divided into three subgroups according to BMI: low BMI (BMI < 18.5 kg/m2; n = 43), normal-weight (control) (BMI 18.5-24.99 kg/m2; n = 21) and overweight/ @entity1 (BMI > 25 kg/m2; n = 20). BMI was calculated, and the following measurements were taken: International Normalized Ratio, antithrombin III, @entity8 ) activity, @entity8 -antigen, plasma fibrinogen level, factor VII, Plasminogen activator inhibitor (PAI)-1 activity and antigen and metabolic parameters: fasting insulin and @entity3 , total @entity2 , HDL- @entity2 , LDL- @entity2 and @entity4 . The results were statistically analyzed. In the low BMI group, a negative correlation between fasting insulin and @entity6 activity, and a positive correlation between fasting @entity3 and @entity6 antigen were observed. Also, a strong negative correlation between @entity6 activity and insulin/ @entity3 index was found. Plasma insulin levels were significantly lower in the low-BMI @entity0 than in the overweight/ @entity1 group (p < 0.001) and with no difference compared to the control group. We did not find any difference in fasting @entity3 level between all groups. HDL- @entity2 showed the highest levels in the normal BMI group and was significantly higher than in the low BMI and @entity1 groups (p < 0.05 and p < 0.01, respectively). @entity6 activity in the low BMI @entity0 revealed @entity7 in comparison to control and overweight/ @entity1 @entity0 (p < 0.001 and p < 0.05, respectively). Lower antigen levels were also shown as compared to both these groups (p < 0.001 and p < 0.001, respectively). Similar results were obtained with @entity8 antigen levels (p < 0.001 and p < 0.001, respectively). There were no differences in activity of @entity8 in all groups. Obese @entity0 showed significantly higher fibrinogen levels than other BMI groups (p < 0.001 and p < 0.001 respectively). Analysis of hemostatic variables in @entity0 with a low BMI testify to the impaired fibrinolysis in this group, also showing a strong correlation with @entity5 metabolism.

title: Hemostatic variables, XXXX metabolism and lipid profile in @entity0 with low body mass index.

answer: @entity5


abstract: The aim of this study was to evaluate hemostatic variables in @entity0 according to different body mass index (BMI) values, and then correlate them with some metabolic parameters - fasting insulin and @entity3 , total @entity2 , high-density lipoprotein (HDL)- @entity2 , low-density lipoprotein (LDL)- @entity2 and @entity4 . Eighty-four female @entity0 aged 18-39 years were recruited, and agreed to participate in the study. The study group was divided into three subgroups according to BMI: low BMI (BMI < 18.5 kg/m2; n = 43), normal-weight (control) (BMI 18.5-24.99 kg/m2; n = 21) and overweight/ @entity1 (BMI > 25 kg/m2; n = 20). BMI was calculated, and the following measurements were taken: International Normalized Ratio, antithrombin III, @entity8 ) activity, @entity8 -antigen, plasma fibrinogen level, factor VII, Plasminogen activator inhibitor (PAI)-1 activity and antigen and metabolic parameters: fasting insulin and @entity3 , total @entity2 , HDL- @entity2 , LDL- @entity2 and @entity4 . The results were statistically analyzed. In the low BMI group, a negative correlation between fasting insulin and @entity6 activity, and a positive correlation between fasting @entity3 and @entity6 antigen were observed. Also, a strong negative correlation between @entity6 activity and insulin/ @entity3 index was found. Plasma insulin levels were significantly lower in the low-BMI @entity0 than in the overweight/ @entity1 group (p < 0.001) and with no difference compared to the control group. We did not find any difference in fasting @entity3 level between all groups. HDL- @entity2 showed the highest levels in the normal BMI group and was significantly higher than in the low BMI and @entity1 groups (p < 0.05 and p < 0.01, respectively). @entity6 activity in the low BMI @entity0 revealed @entity7 in comparison to control and overweight/ @entity1 @entity0 (p < 0.001 and p < 0.05, respectively). Lower antigen levels were also shown as compared to both these groups (p < 0.001 and p < 0.001, respectively). Similar results were obtained with @entity8 antigen levels (p < 0.001 and p < 0.001, respectively). There were no differences in activity of @entity8 in all groups. Obese @entity0 showed significantly higher fibrinogen levels than other BMI groups (p < 0.001 and p < 0.001 respectively). Analysis of hemostatic variables in @entity0 with a low BMI testify to the impaired fibrinolysis in this group, also showing a strong correlation with @entity5 metabolism.

title: Hemostatic variables, @entity5 metabolism and lipid profile in XXXX with low body mass index.

answer: @entity0


abstract: BACKGROUND: Cdk8 is a component of the mediator complex which facilitates transcription by RNA polymerase II and has been shown to play an important role in development of @entity1 . This eukaryote feeds as single cells but starvation triggers the formation of a multicellular organism in response to extracellular pulses of @entity0 and the eventual generation of spores. Strains in which the gene encoding Cdk8 have been disrupted fail to form multicellular aggregates unless supplied with exogenous pulses of @entity0 and later in development, cdk8- cells show a defect in spore production. RESULTS: Microarray analysis revealed that the cdk8- strain previously described (cdk8-HL) contained genome duplications. Regeneration of the strain in a background lacking detectable gene duplication generated strains (cdk8-2) with identical defects in growth and early development, but a milder defect in spore generation, suggesting that the severity of this defect depends on the genetic background. The failure of cdk8- cells to aggregate unless rescued by exogenous pulses of @entity0 is consistent with a failure to express the catalytic subunit of protein kinase A. However, overexpression of the gene encoding this protein was not sufficient to rescue the defect, suggesting that this is not the only important target for Cdk8 at this stage of development. Proteomic analysis revealed two potential targets for Cdk8 regulation, one regulated post-transcriptionally ( @entity2 dioxygenase (HPD)) and one transcriptionally (short chain dehydrogenase/reductase (SDR1)). CONCLUSIONS: This analysis has confirmed the importance of Cdk8 at multiple stages of @entity1 development, although the severity of the defect in spore production depends on the genetic background. Potential targets of Cdk8-mediated gene regulation have been identified in @entity1 which will allow the mechanism of Cdk8 action and its role in development to be determined.

title: Targets downstream of Cdk8 in XXXX development.

answer: @entity1


abstract: @entity7 1 produces a periplasmic protein with multiple toxic effects in vivo and in vitro. These include @entity2 , @entity0 and enterotoxicity, as well as the ability to inhibit cell-free protein synthesis. The purified toxin is a protein of relative molecular mass (Mr) 64 000. It is composed of one catalytically active A subunit (Mr = 32 000) that inhibits protein synthesis, and a complex of five B monomers (Mr approximately 6500 each). Studies using subunit-specific antibodies demonstrate that the B subunit mediates the binding of toxin to toxin receptors in the cell membrane. In a model system in HeLa cell culture, the surface membrane receptor has been shown to be a glycoprotein, most probably @entity3 -linked, and to contain oligomeric beta 1----4 linked @entity5 . Studies with metabolic inhibitors and agents that disrupt the cytoskeleton, and/or alter the pH and function of acidic cytoplasmic vesicles, provide indirect evidence that toxin is transported from the cell surface to the cell interior. This process is probably receptor-mediated endocytosis, since it is also inhibited by @entity4 that prevent receptor-mediated uptake of other ligands in well-characterized systems. The toxic action in the HeLa cell is due to the subsequent inhibition of protein synthesis which results from catalytic inactivation of the 60S ribosomal subunit and the cessation of polypeptide chain elongation. Inhibition of protein synthesis by toxin produced subsequent to bacterial invasion of colonic epithelial cells could explain the destructive lesions found in @entity6 . Although toxin can induce jejunal secretion in animal models, there is at present no clear explanation for the secretory response of the gut mucosa in @entity1 .

title: Shigella toxin and the pathogenesis of XXXX .

answer: @entity6


abstract: Fundamental and clinical studies have been performed on the @entity8 granules (combination of @entity1 ( @entity9 ) and @entity4 ( @entity7 ) in 2: 1 ratio) in the pediatric field. In bacteriological studies a potentiated antibacterial activity of @entity8 was recognized against @entity9 -resistant and beta-lactamase producing clinical isolates. The pharmacokinetics of the @entity8 granules were studied at dose levels from 10 to 20 mg/kg. The peak serum concentrations of @entity9 and CVA achieved approximately 1 hour after dosing were 4.29-9.55 micrograms/ml and 3.87-4.78 micrograms/ml, respectively. The serum half-life was found to be 0.90-1.31 hours for @entity9 and 1.01-1.22 hours for CVA. Six-hour urinary excretion rates were 29.5-62.6% for @entity9 and 12.6-37.9% for CVA. In the clinical studies, the @entity8 granules were administered to 36 pediatric @entity0 (15 with @entity5 , 10 with @entity3 and 11 with skin or soft tissue @entity2 , etc.) at dose levels of 30-50 mg/kg/day. Clinical results in all cases were excellent or good. In particular, good bacterial and clinical effects were obtained against @entity2 caused by beta-lactamase producing @entity9 -resistant strains except @entity6 1 strain. No adverse reactions or abnormal laboratory findings were recognized in any @entity0 .

title: [Experimental and clinical studies on @entity8 ( XXXX - @entity1 ) granules in the pediatric field].

answer: @entity4


abstract: Fundamental and clinical studies have been performed on the @entity8 granules (combination of @entity1 ( @entity9 ) and @entity4 ( @entity7 ) in 2: 1 ratio) in the pediatric field. In bacteriological studies a potentiated antibacterial activity of @entity8 was recognized against @entity9 -resistant and beta-lactamase producing clinical isolates. The pharmacokinetics of the @entity8 granules were studied at dose levels from 10 to 20 mg/kg. The peak serum concentrations of @entity9 and CVA achieved approximately 1 hour after dosing were 4.29-9.55 micrograms/ml and 3.87-4.78 micrograms/ml, respectively. The serum half-life was found to be 0.90-1.31 hours for @entity9 and 1.01-1.22 hours for CVA. Six-hour urinary excretion rates were 29.5-62.6% for @entity9 and 12.6-37.9% for CVA. In the clinical studies, the @entity8 granules were administered to 36 pediatric @entity0 (15 with @entity5 , 10 with @entity3 and 11 with skin or soft tissue @entity2 , etc.) at dose levels of 30-50 mg/kg/day. Clinical results in all cases were excellent or good. In particular, good bacterial and clinical effects were obtained against @entity2 caused by beta-lactamase producing @entity9 -resistant strains except @entity6 1 strain. No adverse reactions or abnormal laboratory findings were recognized in any @entity0 .

title: [Experimental and clinical studies on @entity8 ( @entity4 - XXXX ) granules in the pediatric field].

answer: @entity1


abstract: Fundamental and clinical studies have been performed on the @entity8 granules (combination of @entity1 ( @entity9 ) and @entity4 ( @entity7 ) in 2: 1 ratio) in the pediatric field. In bacteriological studies a potentiated antibacterial activity of @entity8 was recognized against @entity9 -resistant and beta-lactamase producing clinical isolates. The pharmacokinetics of the @entity8 granules were studied at dose levels from 10 to 20 mg/kg. The peak serum concentrations of @entity9 and CVA achieved approximately 1 hour after dosing were 4.29-9.55 micrograms/ml and 3.87-4.78 micrograms/ml, respectively. The serum half-life was found to be 0.90-1.31 hours for @entity9 and 1.01-1.22 hours for CVA. Six-hour urinary excretion rates were 29.5-62.6% for @entity9 and 12.6-37.9% for CVA. In the clinical studies, the @entity8 granules were administered to 36 pediatric @entity0 (15 with @entity5 , 10 with @entity3 and 11 with skin or soft tissue @entity2 , etc.) at dose levels of 30-50 mg/kg/day. Clinical results in all cases were excellent or good. In particular, good bacterial and clinical effects were obtained against @entity2 caused by beta-lactamase producing @entity9 -resistant strains except @entity6 1 strain. No adverse reactions or abnormal laboratory findings were recognized in any @entity0 .

title: [Experimental and clinical studies on XXXX ( @entity4 - @entity1 ) granules in the pediatric field].

answer: @entity8


abstract: AIM: To study the relationship between the radiological anatomy and the dynamics on bile duct sphincter in bile draining and regularizing effect of gallbladder. METHODS: Sixteen healthy @entity0 weighing 18 kg to 25 kg were divided randomly into control group and experimental group (cholecystectomy group). Cineradiography, manometry with perfusion, to effect of endogenous @entity1 and change of ultrastructure were employed. RESULTS: According to finding of the choledochography and manometry, in control group the intraluminal basal pressure of cephalic cyclic smooth muscle of choledochal sphincter cCS was 9.0+/-2.0 mmHg and that of middle oblique smooth muscle of choledochal sphincter ( @entity2 ) was 16.8+/-0.5 mmHg, the intraluminal basal pressure of cCS segment was obviously lower than that of @entity2 (P<0.01) in the interval period of bile draining, but significative difference of intraluminal basal pressure of the @entity2 segment was not found between the interval period of bile draining (16.8+/-0.5 mmHg) and the bile flowing period (15.9+/-0.9 mmHg) (P>0.05). The motility of cCS was mainly characterized by rhythmically concentric contraction, just as motility of cCS bile juice was pumped into the @entity2 segment in control group. And motility of @entity2 segment showed mainly diastolic and systolic activity of autonomically longitudinal peristalsis. There was spasmodic state in cCS and @entity2 segment and reaction to endogenous @entity1 was debased after cholecystectomy. The change of ultrastructure of cCS portion showed mainly that the myofilaments of cell line in derangement and mitochondria is swelling. CONCLUSION: During fasting, the cCS portion has a function as similar cardiac "pump" and it is main primary power source in bile draining, and @entity2 segment serves mainly as secondary power in bile draining. The existence of the intact gallbladder is one of the important factors in guaranteeing the functional coordination between the cCS and @entity2 of bile duct sphincter. There is dysfunction in the cCS and @entity2 with cholecystectomy.

title: The study between the dynamics and the X-ray anatomy and regularizing effect of gallbladder on bile duct sphincter of the XXXX .

answer: @entity0


abstract: AIM: To evaluate the clinical, radiological and microbiological properties of @entity4 ( @entity4 ) and to discuss methods needed to get the diagnosis. METHODS: Thirty-one @entity0 diagnosed as @entity4 between March 1998 and December 2001 at the Gastroenterology Department of Kartal State Hospital, Istanbul, @entity1 were evaluated prospectively. Complete physical examination, medical and family history, blood count erythrocyte sedimentation rate, routine biochemical tests, Mantoux skin test, chest X-ray and abdominal ultrasonography (USG) were performed in all cases, whereas microbiological examination of @entity7 , upper @entity2 , colonoscopy or barium enema, abdominal tomography, mediastinoscopy, laparoscopy or laparotomy were done when needed. RESULTS: The median age of @entity0 (14 females,17 males) was 34.2 years (range 15-65 years). The most frequent symptoms were @entity6 and @entity3 . Eleven @entity0 had active @entity10 . The most common abdominal USG findings were @entity7 and @entity5 . Ascitic fluid analysis performed in 13 @entity0 was found to be exudative and acid resistant bacilli were present in smear and cultured only in one @entity0 with BacTec (3.2 %). Upper @entity2 yielded nonspecific findings in 16 @entity0 . Colonoscopy performed in 20 @entity0 showed @entity8 in 9 (45 %), nodules in 2 (10 %) and, stricture, polypoid lesions, granulomatous findings in terminal ileum and rectal fistula each in one @entity0 (5 %). Laparoscopy on 4 @entity0 showed dilated bowel loops, thickening in the mesentery, multiple @entity8 and tubercles on the peritoneum. @entity0 with @entity4 were divided into three groups according to the type of involvement. Fifteen @entity0 (48 %) had intestinal @entity4 , 11 @entity0 (35.2 %) had @entity11 and 5 (16.8 %) @entity9 . The diagnosis of @entity4 was confirmed microbiologically in 5 (16 %) and histo-pathologically in 19 @entity0 (60.8 %). The remaining nine @entity0 (28.8 %) had been diagnosed by a positive response to antituberculous treatment. CONCLUSION: Neither clinical signs, laboratory, radiological and endoscopic methods nor bacteriological and histopathological findings provide a gold standard by themselves in the diagnosis of @entity4 . However, an algorithm of these diagnostic methods leads to considerably higher precision in the diagnosis of this insidious disease which primarily necessitate a clinical awareness of this serious health problem.

title: A clinical dilemma: XXXX .

answer: @entity4


abstract: Because of the omnipresence of @entity2 belonging to the species Candida it is not easy to distinguish between contamination and @entity1 in @entity0 (e.g. swabs from skin or mucous membranes). Antibody detection may be helpful for the diagnosis of severe @entity3 . However, during early infancy most @entity0 produce Candida antibodies without the signs of @entity1 . Those basic antibody titers have to be considered when antibody determination becomes necessary to prove @entity3 . Lowest titers against Candida were detected in the first year of life based on the decrease of the maternally transmitted antibodies. However, Candida colonization rates are most frequently detectable in this period. At the age of 10 years the antibody titers of adults are reached. The determination of one single titer does not justify any conclusion of @entity3 because the antibody basic titers are widely scattered. @entity3 still remain a more or less clinical diagnosis which can only be confirmed by the antibody titer dynamics.

title: [Antibody base titer against the XXXX fungus of the Candida family in childhood].

answer: @entity2


abstract: Primary @entity1 is the most common form of @entity7 in Australia. The condition presents in a variety of ways, but commonly with synpharyngitic @entity8 , most often in young @entity0 in the third and fourth decades. The course of the disease is indolent but there is progression to @entity5 in up to one quarter of cases. Renal biopsy morphology is variable but the essential immunofluorescence finding is diffuse mesangial IgA staining of greater intensity but often in association with other immunoglobulins. C3 is usually also present. Mesangial cellularity is increased in some two-thirds of cases, one third being of a minor focal or variable extent and one-third diffuse. @entity6 , hyaline nodules and vascular changes are frequent. Crescents are also often present. The etiology of the disease is uncertain but has been linked with HLA antigens, elevated serum IgA levels, IgA polymers, immune complexes and @entity4 cell function. Secondary forms of mesangial IgA deposition occur with @entity2 , hyperglobulinemia or @entity4 hepatobiliary clearance, and these may offer some insight into the immunopathogenesis of the @entity3 .

title: XXXX --accumulated experience and current concepts.

answer: @entity1


abstract: Horizontal genetic exchange strongly influences the evolution of many bacteria, substantially contributing to difficulties in defining their position in taxonomic groups. In particular, how clusters of related bacterial genotypes - currently classified as microbiological species - evolve and are maintained remains controversial. The nature and magnitude of gene exchange between two closely related (approx. 15% @entity0 divergence) microbiologically defined species, @entity1 and @entity3 , was investigated by the examination of mosaic alleles, those with some ancestry from each population. A total of 1738 alleles from 2953 seven-locus housekeeping gene @entity2 ( @entity2 ) were probabilistically assigned to each species group with the model-based clustering algorithm structure. Alleles with less than 75% assignment probability to one of the populations were confirmed as mosaics using the structure linkage model. For each of these, the putative source of the recombinant region was determined and the allele was mapped onto a clonalframe genealogy derived from concatenated ST sequences. This enabled the direction and frequency of introgression between the two populations to be established, with 8.3% of @entity3 clade 1 alleles having acquired @entity1 sequence, compared to 0.5% for the reciprocal process. Once generated, mosaic genes spread within @entity3 clade 1 by a combination of clonal expansion and lateral gene transfer, with some evidence of erosion of the mosaics by reacquisition of @entity3 sequence. These observations confirm previous analyses of the exchange of complete housekeeping alleles and extend this work by describing the processes of horizontal gene transfer and subsequent spread within recipient species.

title: Introgression in the genus XXXX : generation and spread of mosaic alleles.

answer: @entity1


abstract: In this study the effect of local adenoviral-mediated delivery of inducible @entity1 synthase on restenosis was evaluated in a porcine coronary stented model. Local gene transfer of recombinant adenoviral vectors that encode @entity0 inducible @entity1 synthase (AdiNOS) was tested. Control vector (AdNull) lacked a recombinant transgene. Endoluminal delivery of 1.0 x 10(11) adenoviral particles was accomplished in 45 s using the Infiltrator catheter (Interventional Technologies, San Diego, CA). Coronary stents were deployed, oversized by a ratio of 1.2:1, in the treated segments immediately after gene transfer. Fourteen animals were sacrificed at day 28 to evaluate the effects of @entity3 gene transfer on morphometric indices, and 4 animals were sacrificed at day 4 for detection of @entity0 @entity3 expression by RT-PCR. @entity3 mRNA was detected in six of eight @entity3 -transferred arteries, whereas no expression of @entity0 @entity3 was detected in the nontarget arteries. Morphometric analysis showed that @entity3 transfer significantly reduced neointimal formation (3.41 +/- 1.12 mm(2) vs 2.14 +/- 0.68 mm(2), P < 0.05). We concluded that efficient intramural adenovirus-mediated @entity3 transfer can be achieved by using Infiltrator catheters. @entity3 gene transfer significantly reduces neointimal @entity2 following stent injury.

title: Local adenoviral-mediated inducible XXXX synthase gene transfer inhibits neointimal formation in the porcine coronary stented model.

answer: @entity1


abstract: Tea (Camellia sinensis) is one of the most popular beverages, consumed worldwide. The health promoting properties of tea have been attributed to its antioxidative polyphenolic constituents and their oxidative products. The aim of the present study was to evaluate the chemopreventive efficacy of a black tea infusion on @entity3 induced colonic @entity2 , the aberrant crypt foci in @entity0 . @entity0 were injected with @entity3 (15mg/kg.b.w.) and received oral administration of 1% and 2% (w/v) tea infusions from the 1(st)day of carcinogen application. The treatment was continued for 12 weeks. The colons were then assessed for aberrant crypt foci and compared with the untreated carcinogen control group. In situ cell proliferation and in situ apoptosis were also estimated using Brdu incorporation and the TUNEL method, respectively. Aberrant crypt foci were reduced significantly (by 44% in the 1% tea-treated and by about 40% in 2% tea-treated group). Significant decrease in proliferation and increase in apoptosis suggest a possible interplay between the two processes resulting in inhibition of @entity1 by black tea.

title: Inhibition of Cell Proliferation and Induction of Apoptosis During XXXX Induced Colon Carcinogenesis by Black Tea.

answer: @entity3


abstract: BACKGROUND: Open curettage with bone graft has been the traditional surgical treatment for symptomatic unicameral calcaneal @entity4 . Endoscopic procedures have recently provided less invasive techniques with shorter postoperative morbidity. HYPOTHESIS: The authors' endoscopic procedure is effective for young athletes with symptomatic calcaneal @entity4 . STUDY DESIGN: Case series; Level of evidence, 4. METHODS: Of 16 young athletes with symptomatic calcaneal @entity4 , 13 underwent endoscopic curettage and percutaneous injection of bone substitute under the new method. Three @entity0 were excluded because of short-term follow-up, less than 24 months. For the remaining 10 @entity0 , with a mean preoperative 3-dimensional size of 23   31   35 mm as calculated by computed tomography, clinical evaluation was made with the American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale just before surgery and at the most recent follow-up (mean, 36.2 months; range, 24-51 months), and radiologic assessment was performed at the most recent follow-up, to discover any recurrence or pathologic @entity3 . Furthermore, the 10 @entity0 -all of whom returned to sports activities-were asked how long it took to return to initial sports activity level after surgery. RESULTS: Mean ankle-hindfoot scale score improved from preoperative 78.7    4.7 points (range, 74-87) to postoperative 98.0    4.2 points (range, 90-100) (P < .001). @entity2 and functional scores significantly improved after surgery (P < .01 and P < .05, respectively). Radiologic assessment at most recent follow-up revealed no recurrence or pathologic @entity3 , with retention of injected @entity1 cement in all cases. All @entity0 could return to their initial levels of sports activities within 8 weeks after surgery (mean period, 7.1 weeks; range, 4-8 weeks), which was quite early as compared with past reports. CONCLUSION: Endoscopic curettage and injection of bone substitute appears to be an excellent option for young athletes with symptomatic calcaneal @entity4 for early return to sports activities, because it has the possibility to minimize the risk of postoperative pathologic @entity3 and local recurrence after early return to initial level of sports activities.

title: Endoscopic surgery for young athletes with symptomatic unicameral XXXX of the calcaneus.

answer: @entity4


abstract: @entity2 is a congenital, metabolic, nonfamilial disturbance that occurs in one or more bones, at times in association with @entity7 . The authors report on a large personal series of 23 @entity0 with @entity2 involving the craniofacial skeleton. The etiology, clinical findings, pathology, and differential diagnosis of this condition are reviewed and a working hypothesis is offered for the pathophysiology of this disorder. Approximately one-third of @entity0 with @entity2 have involvement of the cranial or facial bones. The authors describe how new techniques in craniofacial surgery have opened up additional options for this group of @entity0 . @entity3 , @entity5 , proptosis, @entity4 , @entity8 , and @entity6 , are some of the clinical features that may require early surgical management. Evidence is given to support more complete resection of @entity1 with immediate reconstruction by several techniques. The removal, remodeling, and replacement of the @entity10 bone is advanced as a promising new method for the management of these complex problems. Successful use of this technique in four @entity0 is reported. In a separate group of @entity0 , continuing good experience is reported with cranio-orbital reconstruction by means of large @entity9 implants. Both of these surgical approaches eliminate donor site morbidity that results from the grafting of large amounts of autogenous bone. Both techniques also avoid the problems associated with postoperative absorption of bone grafting. Several @entity0 are reported in whom serious disturbances in visual function appear to have been prevented or reversed by early treatment. Factors leading to malignant change in @entity0 with @entity2 are reviewed.

title: The surgical treatment of XXXX . With emphasis on recent contributions from cranio-maxillo-facial surgery.

answer: @entity2


abstract: BACKGROUND: Giardia is one of the leading protozoal causes of @entity0 @entity2 . It is prevalent in both developed and developing countries. Currently, @entity3 is the most commonly notified waterborne disease in New Zealand. The aim of the study was to identify potentially modifiable risk factors for @entity1 in the adult population in Auckland. METHODS: This case-control study involved 183 Giardia-positive cases and 336 randomly selected controls, aged between 15 and 64 years. Exposure information was collected retrospectively over the telephone for the 21 days preceding the date of onset of symptoms. Both univariate and multiple logistic regression analyses were carried out. RESULTS: The majority of cases were in the 25-44-year age group and in the New Zealand European ethnic group. Housewives and nursing mothers were at significant risk of the disease (odds ratio (OR)=2.06; 95% CI=1.4-3.74), as were the occupational groups exposed to @entity0 wastes (OR=4.04, 95% CI=1.85-8.85). Consumption of drinking water from New Zealand supplies other than metropolitan mains supplies (OR=2.11, 95% CI=1.36-3.27) or from sources outside New Zealand (OR=7.97, 95% CI=4.20-15.12) represented a significantly higher risk, as did traveling (OR=7.57, 95% CI=4.03-14.23) and swimming in pools or fresh water at least once a week (OR=2.04, 95% CI= 1.33-3.12). CONCLUSIONS: The study identified potentially modifiable risk factors for @entity1 . These findings should be investigated further in different groups and settings to ensure better protection of the public health.

title: Risk of XXXX in Aucklanders: a case-control study.

answer: @entity3


abstract: AIM: To report a case series of @entity0 with persistent temple-related problems following lateral wall rim-sparing (LWRS) orbital decompression for @entity4 and to discuss their management. METHODS: Retrospective review of medical records of @entity0 referred to two oculoplastic centres (Corneoplastic Unit, Queen Victoria Hospital, East Grinstead, UK and Moran Eye Center, University of Utah, Salt Lake City, USA) for intervention to improve/alleviate temple-related problems. All @entity0 were seeking treatment for their persistent, temple-related problems of minimum 3   years' duration post decompression. The main outcome measure was the resolution or improvement of temple-related problems. RESULTS: Eleven orbits of six @entity0 (five females) with a median age of 57   years (range 23-65) were included in this study. Temple-related problems consisted of cosmetically bothersome temple hollowness (n=11; 100%), @entity5 (n=8; 73%), temple tenderness (n=4; 36%), 'clicking' sensation (n=4; 36%) and gaze-evoked @entity3 (n=4; 36%). Nine orbits were also complicated by proptosis and @entity2 . Preoperative imaging studies showed the absence of lateral wall in all 11 orbits and evidence of prolapsed lacrimal gland into the wall defect in four orbits. Intervention included the repair of the lateral wall defect with a sheet implant, orbital decompression involving fat, the medial wall or orbital floor and autologous fat transfer or synthetic filler for temple hollowness. Postoperatively, there was full resolution of @entity5 , temple tenderness, 'clicking' sensation and gaze-evoked @entity3 , and an improvement in temple hollowness. Pre-existing @entity1 in one @entity0 resolved after surgery while two @entity0 developed new-onset @entity1 necessitating strabismus surgery. CONCLUSIONS: This is the first paper to show that persistent, troublesome temple-related problems following LWRS orbital decompression can be surgically corrected. @entity0 should be counselled about the potential risk of these complications when considering LWRS orbital decompression.

title: Surgical management of temple-related problems following lateral wall rim-sparing orbital decompression for XXXX .

answer: @entity4


abstract: BACKGROUND AND AIMS: Dysfunction of physiological regulation systems may underlie the disrupted emotional and self-regulatory processes among @entity0 with @entity1 ( @entity1 ). This paper reviews evidence as to whether or not respiratory sinus @entity2 (RSA), as a psychophysiological index of emotional regulation, could provide useful information in treatment-outcome research to provide insights into recovery processes. METHODS: We reviewed the use of RSA in clinical research and studies on @entity1 treatment. Search terms for the review of RSA in clinical research included respiratory sinus @entity2 , heart rate variability, vagal, cardiac vagal control, psychophysiology, intervention, treatment, mindfulness, mind-body, mental health, substance use, chemical dependence, regulation and emotion regulation. For the review of RSA in intervention studies, we included only those that provided adequate description of psychophysiological methods, and examined RSA in the context of an intervention study. RESULTS: RSA appears to be able to provide an index of self-regulatory capacity; however, it has been little used in either intervention or treatment research. Of the four intervention studies included in this review, all were mindfulness-based interventions. Two studies were with substance-using samples, and both showed pre-post increases in RSA and related improved substance use outcomes. Two of the three studies were randomized controlled trials (RCTs), and both showed significant increases in RSA in the experimental compared to comparison condition. CONCLUSION: Respiratory sinus @entity2 may be a useful index of emotional regulation in @entity0 with @entity1 , and a potential measure of underlying mechanisms for @entity1 treatment studies, particularly mindfulness-based interventions.

title: Respiratory sinus XXXX as a potential measure in substance use treatment-outcome studies.

answer: @entity2


abstract: BACKGROUND: @entity1 is received by millions of @entity0 in the United States and elsewhere and will remain the most commonly used anticoagulant for the foreseeable future. Percent time in therapeutic range (TTR) with @entity1 is increasingly used as a performance measure. However, stakeholders have expressed concern that TTR lags behind changes in performance. Work in a larger study focused on the impact of shortening the conventional measurement period for TTR. METHODS: Some 124 sites within the Department of Veterans Affairs (VA) were examined during a seven-year period (fiscal years [FYs] 2008-2014 (April 1, 2007-September 30, 2014). The duration of time segments (2, 3, 4, 6 months) used to calculate TTR were varied, and these four durations were compared in terms of the number of @entity0 retained per site, mean and median site TTR, and site performance rankings. RESULTS: Data were obtained on 295,237 unique @entity0 who received anticoagulation. As the calculation window shortened, @entity0 with better control (that is, higher TTR) were selectively excluded from the measurement because their laboratory values were more widely spaced. Site mean TTR was highest when the most @entity0 were included (6 months: 950 @entity0 ; TTR 65.2%) and lowest when the fewest @entity0 were included (2 months: 567 @entity0 ; TTR 60.0%). However, the 3-, 4-, and 6-month segments achieved similar results, each of which included more than 800 @entity0 per site, with mean TTR across a narrow range (64.9%-65.2%). Site rankings were less highly correlated between the 2-month period and longer periods (r = 0.7- 0.8) but were otherwise 0.95 or higher, with a nearly perfect correlation (0.985) between the 4- and 6-month periods. CONCLUSIONS: When TTR is used to measure site-level performance, comparable results can be achieved using a 4- or a 6-month measurement period. On the basis of these results, the use of a 4-month period for future measurement efforts is recommended.

title: Percent Time in Range with XXXX as a Performance Measure: How Long a Sampling Frame Is Needed?

answer: @entity1


abstract: PURPOSE: To define a new clinical entity in a consanguineous family with six @entity0 affected by @entity7 , including @entity3 , @entity4 , @entity6 , @entity2 , and platyspondyly. To analyze candidate genes of @entity8 as a possible underlying disorder and to demonstrate especially the ocular phenotype. DESIGN: Observational case series. METHODS: Consanguineous parents, one unaffected sibling and five affected @entity0 with clinical features of spondylo-ocular syndrome, were demonstrated. Clinical examination, radiologic, laboratory, and cytogenetic as well as moleculargenetic analyses were performed. The segregation of flanking marker alleles of three collagen genes and the interval for @entity11 were analyzed. Two microsatellite markers located within Pax6CA/GT region were tested for homozygosity. RESULTS: On laboratory investigation a normal excretion of @entity5 , mucopolysaccharides, and oligosaccharides could be found. The karyotype was normal. Complete radiologic examination in one index @entity0 revealed a generalized moderate @entity2 , platyspondyly with fish bone appearance, and greatly enlarged intervertebral spaces. The candidate genes known to be in @entity9 as well as linkage to the @entity11 candidate region could be excluded. None of the affected showed homozygosity for the @entity10 microsatellite markers. CONCLUSIONS: We conclude that the phenotype and the clinical features in this family defines a new @entity1 . It remains to be seen what kind of molecule shared by eye and bone is involved.

title: XXXX : a new entity with @entity4 , @entity3 , @entity6 , @entity2 , and platyspondyly.

answer: @entity7


abstract: PURPOSE: To define a new clinical entity in a consanguineous family with six @entity0 affected by @entity7 , including @entity3 , @entity4 , @entity6 , @entity2 , and platyspondyly. To analyze candidate genes of @entity8 as a possible underlying disorder and to demonstrate especially the ocular phenotype. DESIGN: Observational case series. METHODS: Consanguineous parents, one unaffected sibling and five affected @entity0 with clinical features of spondylo-ocular syndrome, were demonstrated. Clinical examination, radiologic, laboratory, and cytogenetic as well as moleculargenetic analyses were performed. The segregation of flanking marker alleles of three collagen genes and the interval for @entity11 were analyzed. Two microsatellite markers located within Pax6CA/GT region were tested for homozygosity. RESULTS: On laboratory investigation a normal excretion of @entity5 , mucopolysaccharides, and oligosaccharides could be found. The karyotype was normal. Complete radiologic examination in one index @entity0 revealed a generalized moderate @entity2 , platyspondyly with fish bone appearance, and greatly enlarged intervertebral spaces. The candidate genes known to be in @entity9 as well as linkage to the @entity11 candidate region could be excluded. None of the affected showed homozygosity for the @entity10 microsatellite markers. CONCLUSIONS: We conclude that the phenotype and the clinical features in this family defines a new @entity1 . It remains to be seen what kind of molecule shared by eye and bone is involved.

title: @entity7 : a new entity with @entity4 , @entity3 , @entity6 , XXXX , and platyspondyly.

answer: @entity2


abstract: PURPOSE: To define a new clinical entity in a consanguineous family with six @entity0 affected by @entity7 , including @entity3 , @entity4 , @entity6 , @entity2 , and platyspondyly. To analyze candidate genes of @entity8 as a possible underlying disorder and to demonstrate especially the ocular phenotype. DESIGN: Observational case series. METHODS: Consanguineous parents, one unaffected sibling and five affected @entity0 with clinical features of spondylo-ocular syndrome, were demonstrated. Clinical examination, radiologic, laboratory, and cytogenetic as well as moleculargenetic analyses were performed. The segregation of flanking marker alleles of three collagen genes and the interval for @entity11 were analyzed. Two microsatellite markers located within Pax6CA/GT region were tested for homozygosity. RESULTS: On laboratory investigation a normal excretion of @entity5 , mucopolysaccharides, and oligosaccharides could be found. The karyotype was normal. Complete radiologic examination in one index @entity0 revealed a generalized moderate @entity2 , platyspondyly with fish bone appearance, and greatly enlarged intervertebral spaces. The candidate genes known to be in @entity9 as well as linkage to the @entity11 candidate region could be excluded. None of the affected showed homozygosity for the @entity10 microsatellite markers. CONCLUSIONS: We conclude that the phenotype and the clinical features in this family defines a new @entity1 . It remains to be seen what kind of molecule shared by eye and bone is involved.

title: @entity7 : a new entity with @entity4 , XXXX , @entity6 , @entity2 , and platyspondyly.

answer: @entity3


abstract: PURPOSE: To define a new clinical entity in a consanguineous family with six @entity0 affected by @entity7 , including @entity3 , @entity4 , @entity6 , @entity2 , and platyspondyly. To analyze candidate genes of @entity8 as a possible underlying disorder and to demonstrate especially the ocular phenotype. DESIGN: Observational case series. METHODS: Consanguineous parents, one unaffected sibling and five affected @entity0 with clinical features of spondylo-ocular syndrome, were demonstrated. Clinical examination, radiologic, laboratory, and cytogenetic as well as moleculargenetic analyses were performed. The segregation of flanking marker alleles of three collagen genes and the interval for @entity11 were analyzed. Two microsatellite markers located within Pax6CA/GT region were tested for homozygosity. RESULTS: On laboratory investigation a normal excretion of @entity5 , mucopolysaccharides, and oligosaccharides could be found. The karyotype was normal. Complete radiologic examination in one index @entity0 revealed a generalized moderate @entity2 , platyspondyly with fish bone appearance, and greatly enlarged intervertebral spaces. The candidate genes known to be in @entity9 as well as linkage to the @entity11 candidate region could be excluded. None of the affected showed homozygosity for the @entity10 microsatellite markers. CONCLUSIONS: We conclude that the phenotype and the clinical features in this family defines a new @entity1 . It remains to be seen what kind of molecule shared by eye and bone is involved.

title: @entity7 : a new entity with XXXX , @entity3 , @entity6 , @entity2 , and platyspondyly.

answer: @entity4


abstract: PURPOSE: To define a new clinical entity in a consanguineous family with six @entity0 affected by @entity7 , including @entity3 , @entity4 , @entity6 , @entity2 , and platyspondyly. To analyze candidate genes of @entity8 as a possible underlying disorder and to demonstrate especially the ocular phenotype. DESIGN: Observational case series. METHODS: Consanguineous parents, one unaffected sibling and five affected @entity0 with clinical features of spondylo-ocular syndrome, were demonstrated. Clinical examination, radiologic, laboratory, and cytogenetic as well as moleculargenetic analyses were performed. The segregation of flanking marker alleles of three collagen genes and the interval for @entity11 were analyzed. Two microsatellite markers located within Pax6CA/GT region were tested for homozygosity. RESULTS: On laboratory investigation a normal excretion of @entity5 , mucopolysaccharides, and oligosaccharides could be found. The karyotype was normal. Complete radiologic examination in one index @entity0 revealed a generalized moderate @entity2 , platyspondyly with fish bone appearance, and greatly enlarged intervertebral spaces. The candidate genes known to be in @entity9 as well as linkage to the @entity11 candidate region could be excluded. None of the affected showed homozygosity for the @entity10 microsatellite markers. CONCLUSIONS: We conclude that the phenotype and the clinical features in this family defines a new @entity1 . It remains to be seen what kind of molecule shared by eye and bone is involved.

title: @entity7 : a new entity with @entity4 , @entity3 , XXXX , @entity2 , and platyspondyly.

answer: @entity6


abstract: BACKGROUND: School-located vaccination against @entity1 (SLV-I) has the potential to improve current suboptimal @entity1 immunization coverage for U.S. school-aged @entity0 . However, little is known about SLV-I's cost-effectiveness. The objective of this study is to establish the cost-effectiveness of SLV-I based on a two-year community-based randomized controlled trial (Year 1: 2009-2010 vaccination season, an unusual H1N1 pandemic @entity1 season, and Year 2: 2010-2011, a more typical @entity1 season). METHODS: We performed a cost-effectiveness analysis on a two-year randomized controlled trial of a Western New York SLV-I program. SLV-I clinics were offered in 21 intervention elementary schools (Year 1 n   =   9,027; Year 2 n   =   9,145 @entity0 ) with standard-of-care (no SLV-I) in control schools (Year 1 n   =   4,534 (10 schools); Year 2 n   =   4,796 @entity0 (11 schools)). We estimated the cost-per-vaccinated @entity0 , by dividing the incremental cost of the intervention by the incremental effectiveness (i.e., the number of additionally vaccinated students in intervention schools compared to control schools). RESULTS: In Years 1 and 2, respectively, the effectiveness measure (proportion of @entity0 vaccinated) was 11.2 and 12.0 percentage points higher in intervention (40.7  % and 40.4  %) than control schools. In year 2, the cost-per-vaccinated @entity0 excluding vaccine purchase ( 59.88 in 2010 US  ) consisted of three component costs: (A) the school costs ( 8.25); (B) the project coordination costs ( 32.33); and (C) the vendor costs excluding vaccine purchase ( 16.68), summed through Monte Carlo simulation. Compared to Year 1, the two component costs (A) and (C) decreased, while the component cost (B) increased in Year 2. The cost-per-vaccinated @entity0 , excluding vaccine purchase, was  59.73 (Year 1) and  59.88 (Year 2, statistically indistinguishable from Year 1), higher than the published cost of providing @entity1 vaccination in medical practices ( 39.54). However, taking indirect costs (e.g., averted parental costs to visit medical practices) into account, vaccination was less costly in SLV-I ( 23.96 in Year 1,  24.07 in Year 2) than in medical practices. CONCLUSIONS: Our two-year trial's findings reinforced the evidence to support SLV-I as a potentially favorable system to increase childhood @entity1 vaccination rates in a cost-efficient way. Increased efficiencies in SLV-I are needed for a sustainable and scalable SLV-I program.

title: Cost effectiveness analysis of Year 2 of an elementary school-located XXXX vaccination program-Results from a randomized controlled trial.

answer: @entity1